FIELD: chemistry.
SUBSTANCE: invention relates to a compound having structure
, radicals are as described in the formula of invention, as well as pharmaceutically-acceptable salt, prodrug, tautomer and stereoisomer thereof. The invention also relates to a composition, a set for modulating PPAR based on said compound, a method of treating a patient suffering from a disease or condition or at risk of a disease or condition, for which PPAR modulation is therapeutically useful.
EFFECT: novel compounds which are active towards PPAR are obtained and described.
41 cl, 622 ex, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PYRROLO[2,3-B]PYRIDINE DERIVATIVE AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2418800C2 |
| OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL FOR TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2815636C1 |
| OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2734261C2 |
| OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2719422C2 |
| NEW COMPOUND AS A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND | 2019 |
|
RU2785734C1 |
| FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | 2012 |
|
RU2650641C2 |
| ROUTES OF APPLICATION OF PHOSPHODIESTERASE INHIBITORS | 2020 |
|
RU2795503C2 |
| HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2764243C2 |
| 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE, AND THEIR APPLICATION | 2004 |
|
RU2348617C2 |
| COMPOUNDS, WHICH ARE ACTIVE TOWARDS RECEPTORS, ACTIVATED BY PEROXISOME PROLIFERATOR | 2004 |
|
RU2356889C2 |
